Abrupt-onset diabetes mellitus secondary to pembrolizumab

Endocrinol Diabetes Nutr (Engl Ed). 2023 Jan;70(1):71-73. doi: 10.1016/j.endien.2022.06.013. Epub 2023 Jan 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Diabetes Mellitus, Type 1*
  • Humans

Substances

  • pembrolizumab
  • Antibodies, Monoclonal, Humanized